Catch-22? Supplements May Be Trapped By FDA’s Risk/Benefit Standard
This article was originally published in The Tan Sheet
Executive Summary
Some legal experts contend that a glass ceiling built into FDA's risk/benefit analysis of dietary supplements could leave certain products more vulnerable to regulatory scrutiny in the wake of the agency's outright ban of ephedra